In 2024, Catherine Owen Adams earned $955.94K in total compensation at Acadia Pharmaceuticals, including $245.77K salary and $196.72K bonus. 1+ years at the helm of Acadia Pharmaceuticals.
Compensation History
Annual executive compensation data for Catherine Owen Adams, including salary, bonuses, and stock awards.
Year
2024
Total Compensation
$955.94K
Salary
$245.77K
Bonus
$196.72K
Other
$513.45K
Salary
$245.77KBoard Justification
The Company’s executive compensation policies are designed to: align executive compensation with business objectives and corporate performance; attract and retain executive officers who contribute to the Company’s long-term success; reward and motivate executive officers who contribute to operating and financial performance; and link executive officer compensation and stockholder interests through the grant of long-term incentives.
Bonus
$196.72KBoard Justification
Ms. Owen Adams was entitled to a prorated bonus at target for her services in 2024 under an employment agreement with the Company. The total annual cash incentive percentage, therefore, was 87.4% of target for each executive.
Other Compensation
$513.45KBoard Justification
All Other Compensation includes $12,288 in employer 401(k) matching and a sign-on cash bonus of $500,000 paid to Ms. Owen Adams upon commencement of employment in September 2024. If Ms. Owen Adams voluntarily resigns without Good Reason or is terminated for Cause within two years of her start date, excluding termination due to death or disability, Ms. Owen Adams is required to repay a prorated portion of the sign-on bonus. The repayment amount will be based on the number of months remaining in the 24-month period following the start date.
Restricted Stock
Board Justification
No stock vested for Catherine Owen Adams in 2024.
Performance Metrics
For 2024, the Board established corporate goals related to the following categories: NUPLAZID net product sales, NUPLAZID Profitability, DAYBUE net product sales, Enrollment in ACP-204 Phase 2/3 study in Alzheimer’s disease psychosis, Enrollment in ACP-101 Phase 3 study in Prader-Willi syndrome, Early-stage research and development goals, Positive top-line results in pimavanserin NSS Phase 3 study, and Business development transactions.
Catherine Owen Adams
CEO of Acadia Pharmaceuticals
Education
BSc. in Pharmacy from the University of Manchester
Sector of Economy
Healthcare
CEO of Acadia Pharmaceuticals for
1 year 2 months (Sep 2024 - Present)
Previous Experience
Unknown
Other Acadia Pharmaceuticals CEOs
Holdings
Track Catherine Owen Adams's stock holdings and portfolio value over time.
Insider Trading
Catherine Owen Adams's recent stock transactions, purchases, and sales filed with the SEC.
No insider trades found for this CEO.
Rivals
Compare Catherine Owen Adams with competitor CEOs and industry peers.